Brukinsa Now FDA Approved for Patients with CLL or SLL

JHOP - February 2023 Vol 13, No 1 - FDA Oncology Update

On January 19, 2023, the FDA approved zanubrutinib (Brukinsa; BeiGene USA), a BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The FDA granted zanubrutinib an orphan drug designation for this indication.

Zanubrutinib was previously approved for mantle-cell lymphoma, Waldenström’s macroglobulinemia, and relapsed or refractory marginal-zone lymphoma.

This new approval for CLL or SLL was based on results of several studies and cohorts. In the SEQUOIA study, a cohort of 479 patients with treatment-naïve CLL or SLL and no 17p deletion were randomized (1:1) to zanubrutinib monotherapy until disease progression or unacceptable adverse events or to bendamustine plus rituximab for 6 cycles. The main efficacy measure was progression-free survival (PFS). At an estimated median follow-up of 25 months, the median PFS was not reached (95% confidence interval [CI], not estimable) in the zanubrutinib arm versus 33.7 months (95% CI, 28.1-not estimable) in the bendamustine plus rituximab arm (hazard ratio, 0.42; 95% CI, 0.28-0.63; P ≤.001).

In a separate, nonrandomized, cohort of the SEQUOIA study, 110 patients with treatment-naïve CLL or SLL and 17p deletion received zanubrutinib monotherapy. The overall response rate (ORR) was 88% (95% CI, 81-94). At a median follow-up of 25.1 months, the median duration of response (DOR) was not reached.

A second study called ALPINE included 652 patients with relapsed or refractory CLL or SLL who were randomized (1:1) to zanubrutinib or to another BTK inhibitor—ibrutinib. The median number of previous lines of therapy in this study was 1 (range, 1-8). The ORR was 80% (95% CI, 76-85) in the zanubrutinib arm versus 73% (95% CI, 68-78) in the ibrutinib arm (response rate, 1.10; 95% CI, 1.01-1.20; P = .0264). At a median follow-up of 14.1 months, the median DOR was not reached in either arm.

Across the different cohorts and studies, the most common (≥30%) adverse events with zanubrutinib were decreased neutrophil count (42%), upper respiratory tract infection (39%), platelet count decreased (34%), hemorrhage (30%), and musculoskeletal pain (30%). In addition, 3.7% of patients had atrial fibrillation or flutter, and 0.2% of the patients had grade ≥3 ventricular arrhythmias. In all, 13% of patients had second primary malignancies.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: